Public Advisory - Recall of one lot of pms-Hydromorphone due to packaging error that could potentially lead to overdose
OTTAWA, ON, Aug. 20, 2022 /CNW/ -
Summary
Product: pms-Hydromorphone, 2 mg tablets (DIN 00885436) marketed by Pharmascience Inc. Sold to pharmacies in bottles of 100 tablets for dispensing to consumers.
Issue: Health product ? product safety
What to do: Check your bottle of pms-Hydromorphone to ensure you have the correct tablets. Stop using product from the affected lot and contact your pharmacy immediately for a replacement product.
Who this is for: General public and pharmacists
Product Image(s):
2 mg: Round, biconvex, orange tablet debossed and half-scored with "2"on one side of the tablet and "pms" on the other side.
8 mg: Round, biconvex, white tablet debossed and half-scored with "8"on one side of the tablet and "pms" on the other side.
Affected products
Product
DIN
Lot
Expiry date
Pharmascience Inc. pms-Hydromorphone 2 mg Hydromorphone Hydrochloride Tablets
Bottles of 100 tablets
00885436
639268
31-01-2026
Issue
Pharmascience Inc. is recalling one lot of pms-Hydromorphone, 2 mg tablets, (lot 639268) as the bottles may contain hydromorphone tablets of a different strength (8 mg), meaning they contain higher amounts of hydromorphone. Products from the affected lot were sold between May 2022 and August 2022.
The 2 mg hydromorphone tablets are round and orange with a "2" on one side of the tablet and "pms" on the other side. The 8 mg hydromorphone tablets are round and white with an "8" on one side of the tablet and "pms" on the other side.
Hydromorphone is an opioid medication used to treat pain and opioid use disorder.
Accidentally taking too much hydromorphone (one dose of 8 mg of hydromorphone instead of one dose of 2 mg) or suddenly increasing the dose of hydromorphone could potentially lead to an overdose, which can be life-threatening even in people who have some tolerance to opioids.
Symptoms of hydromorphone overdose may include: dizziness, drowsiness, confusion, slow heartbeat, slow and difficult breathing, cold and clammy skin, seizure, coma and death.
Patients and their caregivers should be aware of the signs and symptoms of hydromorphone overdose, and should seek medical attention immediately if any of these symptoms are noted. If naloxone is available, be prepared to administer it.
The Department is monitoring the company's recall and will inform the public if any new health risks are identified.
What you should do
Check your bottle of pms-Hydromorphone to ensure you have the correct tablets. The 2 mg hydromorphone tablets are round and orange with a "2" on one side of the tablet and "pms" on the other side. The 8 mg hydromorphone tablets are round and white with an "8" on one side of the tablet and "pms" on the other side.
Stop using product from the affected lot and contact your pharmacy immediately for a replacement product.
If you have accidentally taken the 8 mg hydromorphone tablet instead of the 2 mg hydromorphone tablet and you have any health concerns, or are unsure whether you have taken too much hydromorphone, contact your healthcare professional, hospital emergency department or regional poison control centre immediately, even if there are no symptoms. If naloxone is available, be prepared to administer it.
If you have any questions about the recall, contact Pharmascience Inc. at [email protected] or 1-888-550-6060.
Alert / recall type: Public Advisory Category: Drugs Companies: If you have any questions about the recall, contact Pharmascience Inc. at [email protected] or 1-888-550-6060. Published by: Health Canada
Chemistree Technology Inc. and (US OTC: CHMJF) (the "Company" or "Chemistree"), announces that its board of directors (the "Board") has approved a restructuring transaction (the "Restructuring Transaction"), pursuant to which all of the principal of...
United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, will unveil its latest MRI technology, boasting incredible advancements across various fronts, as a Gold sponsor at this year's ISMRM meeting.
The...
In the news release, Mitsubishi Tanabe Pharma America to Present RADICAVA ORS® (edaravone) Real-World Data at the Professional Society for Health Economics and Outcomes Research 2024 Annual Meeting, issued 03-May-2024 by Mitsubishi Tanabe Pharma...
Affiliated Dermatologists (AD) is providing notice of a recent data security incident. At this time, AD is not aware of any misuse of any personal information in connection with this incident.
What Happened?
On March 5, 2024, AD detected it was the...
With recent news of dairy cattle in the United States testing positive for the Highly Pathogenic Avian Influenza (HPAI) and reports of fragments of HPAI detected in pasteurized milk sold in the U.S., we understand that Canadians may be concerned...
Butterfly Medical Ltd, an early-stage medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), is excited to announce the hiring of Patrick MacCarthy as CEO. ...